A pretty cool and hopefully impactful down the road development…
"A Carribean doctor with a background in academia and in heading up a small pharmaceutical company refuses to sell to Big Pharma a medicine that could treat all blood cancer types.
In a rare and important move, the U.S. Food and Drug Administration (FDA) has recently granted special, preliminary approval to a cannabis-based drug being used to treat several blood cancer types.
Chrysoeriol, a new drug that has shown promise in combatting acute myeloid leukemia (AML), has been granted approval under the FDA’s Orphan Drug Act. The law, passed in 1983, allows expedited approval for drugs that treat rare diseases, such as Huntington’s Disease, Muscular Dystrophy, and ALS.
The special designation does not mean the US can manufacture and sell the drug. Rather, it allows its maker certain tax breaks and benefits in order to get the drug to market.
This is a very big deal.
* * * * *
It makes sense that Chrysoeriol is an orphan drug. As far as Big Pharma is concerned, it was born without parents.
The drug was developed by a Caribbean scientist named Henry Lowe, a former academic and CEO of a small pharmaceutical company called Medicanja, the first medical cannabis company in Jamaica.
The news about Chrysoeriol marks the first time the FDA has granted orphan drug approval to a medicine created in a developing country. But if Lowe has his way, it won’t be the last."
* * * * *
Chryosoeirol is not the only good thing to come out of Henry Lowe’s laboratory. He’s applied for several patents and shows no sign of slowing his research.
Dr. Lowe’s treatments could revolutionize the way we understand — and treat — all kinds of cancer. With a new approach and an eye toward a patient-first model of treatment, Lowe’s impact could reach far beyond blood cancer types and spur on a new kind of people-centric oncological care.
And he’s not alone. Lowe attended both Harvard and the Massachusetts Institute of Technology. He is a business man and philanthropist, but not in the way typical of American elites. He wants to lift his own country out of poverty and help cancer patients lead better, longer lives.
That’s why he didn’t take the $50 million he Big Pharma offered him. Instead, he’s trying to raise $3.5 million towards further independent testing. The future of blood cancer treatment looks very promising, thanks to Dr. Lowe.
* * * * *
Much more in the story. And we don't need to add a thing.
Doc Refuses To Sell Cannabis-Based Leukemia Med To Big Pharma
Of all blood cancer types, AML may be the most deadly. But Dr Henry Lowe is stepping in with his new cancer treatment with a strong defense for patients.